News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Changchun BCHT Biotech Acquires Flu Vaccine Technology



2/10/2012 12:24:27 PM

February 10, 2012 -- Changchun BCHT Biotechnology obtained an exclusive license for a live attenuated influenza (LIAV) vaccine technology from BioDiem, an Australian vaccine company. The license gives BCHT exclusive China rights to the technology for an egg-based production method in pandemic and seasonal influenza vaccines. Although the license is limited to LAIV for private market vaccines, BCHT holds a second license to LAIV for China’s public market in China via a sub-license from the World Health Organization. More details....

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES